【Ended】March 2 (Sat) Intestinal Environment Seminar @ Luke’s Ashiya Clinic

Blog

Blog

2019.02.14

Dr. Masahiko Shirotani, Director of Luke’s Ashiya Clinic and Executive Director of our study group, will hold a seminar on March 2 (Sat.) from 3:00 p.m.
Dr. Masahiko Shirotani, Director of Luke’s Ashiya Clinic and Executive Director of our study group, will hold a seminar on intestinal environment.
Please register as soon as possible as seats are limited.
↓Please register as soon as possible.

The seminar has ended.

« Prev Next »

Other Blog

TOILET SEAT STRETCH” RELIEVES CONSTIPATION ON THE TOILET SEAT AND INCREASES THE FECAL VALUE.

In this issue, we will introduce stretches that can relieve constipation. It is often said that an imbalance in the intestinal flora can cause constipation or diarrhea, and that we should adjust the intestinal flora by eating fiber and exercising moderately. However, the opposite is also true. In other words, ongoing constipation further deteriorates the intestinal flora balance, causing abdominal discomfort and gas. When intestinal flora imbalance leads to constipation, it is often difficult to cure it with diet and […]

2023.08.23

Seven articles to improve intestinal flora balance through diet

About 100 trillion intestinal bacteria live in the intestines and perform many very important functions for physical and mental health.They are generally called “good bacteria,” “bad bacteria,” or “opportunistic bacteria,” but they are all necessary. There are as many as 30,000 types of intestinal bacteria that have been found at this point in time.The type and balance of bacteria each person has is different, and this balance is called “intestinal flora balance. A wide variety of intestinal bacteria live in […]

2023.08.18

U.S. FDA APPROVES FIRST FECAL MICROFLORA PRODUCT

On November 30, 2022, the U.S. Food and Drug Administration (FDA) approved FerringPharma’s fecal microbiota product, Rebyota, for the treatment of rCDI, the first time the FDA has approved a fecal microbiota product. Rebyota is approved for the prevention of recurrent recurrent Clostridioides difficile infection (CDI) in patients 18 years of age and older. The drug is intended for patients 18 years of age and older with recurrent CDI who have completed treatment with antibiotic therapy and is administered as […]

2022.12.26

Related Sites